These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 11593107)

  • 21. Hypertension, its treatment, hyperuricaemia and gout.
    Gibson TJ
    Curr Opin Rheumatol; 2013 Mar; 25(2):217-22. PubMed ID: 23370375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension.
    Neutel JM; Smith D
    J Int Med Res; 2005; 33(6):620-31. PubMed ID: 16372579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
    Rayner BL; Trinder YA; Baines D; Isaacs S; Opie LH
    Am J Hypertens; 2006 Feb; 19(2):208-13. PubMed ID: 16448895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.
    Sasso FC; Carbonara O; Persico M; Iafusco D; Salvatore T; D'Ambrosio R; Torella R; Cozzolino D
    Diabetes Care; 2002 Nov; 25(11):1909-13. PubMed ID: 12401731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
    Shahinfar S; Simpson RL; Carides AD; Thiyagarajan B; Nakagawa Y; Umans JG; Parks JH; Coe FL
    Kidney Int; 1999 Nov; 56(5):1879-85. PubMed ID: 10571797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
    Hamada T; Mizuta E; Kondo T; Hirai M; Yamada K; Kato M; Shigemasa C; Yamamoto Y; Ninomiya H; Igawa O; Hisatome I
    Arzneimittelforschung; 2010; 60(2):71-5. PubMed ID: 20329654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
    Lacourcière Y; Asmar R
    Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
    Wang J; Qiu B; Du JL; Deng SB; Liu YJ; She Q
    J Clin Pharmacol; 2015 Dec; 55(12):1362-8. PubMed ID: 26053853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. AT1 blockers and uric acid metabolism: are there relevant differences?
    Puig JG; Torres R; Ruilope LM
    J Hypertens Suppl; 2002 Jun; 20(5):S29-31. PubMed ID: 12184060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
    Ruff D; Gazdick LP; Berman R; Goldberg AI; Sweet CS
    J Hypertens; 1996 Feb; 14(2):263-70. PubMed ID: 8728306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.
    Hallberg P; Karlsson J; Kurland L; Lind L; Kahan T; Malmqvist K; Ohman KP; Nyström F; Melhus H
    J Hypertens; 2002 Oct; 20(10):2089-93. PubMed ID: 12359989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
    Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
    Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irbesartan treatment in hypertension.
    Brown MJ
    Hosp Med; 1998 Oct; 59(10):808-11. PubMed ID: 9850301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension.
    Kochar M; Guthrie R; Triscari J; Kassler-Taub K; Reeves RA
    Am J Hypertens; 1999 Aug; 12(8 Pt 1):797-805. PubMed ID: 10480473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
    Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan.
    Bunt T
    Clin Ther; 1999 Mar; 21(3):611-2. PubMed ID: 10321426
    [No Abstract]   [Full Text] [Related]  

  • 40. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.